Interventions and outcomes of patients with multiple myeloma receiving salvage therapy after BCMA-directed CAR T therapy
Oliver Van Oekelen(Icahn School of Medicine at Mount Sinai), Samir Parekh(The Ohio State University Wexner Medical Center), Saad Z. Usmani(Memorial Sloan Kettering Cancer Center), Tasmin Farzana(United States Fish and Wildlife Service), Gunjan L. Shah(Cornell University), Urvi A. Shah(United States Fish and Wildlife Service), Sundar Jagannath(Mount Sinai Hospital), Joshua Richter(Tisch Hospital), Alexander M. Lesokhin(Memorial Sloan Kettering Cancer Center), Cesar Rodriguez(Wake Forest University), Karthik Nath(United States Fish and Wildlife Service), Shambavi Richard(Medical Oncology Hematology Consultants), Adriana Rossi(Icahn School of Medicine at Mount Sinai), Tarek H. Mouhieddine(Icahn School of Medicine at Mount Sinai), Sham Mailankody(Memorial Sloan Kettering Cancer Center), Larysa Sanchez(Icahn School of Medicine at Mount Sinai), David T. Melnekoff(Icahn School of Medicine at Mount Sinai), Sergio Giralt(Memorial Sloan Kettering Cancer Center), Adolfo Aleman(Icahn School of Medicine at Mount Sinai), Yogita Ghodke‐Puranik(Icahn School of Medicine at Mount Sinai), Hearn Jay Cho(Multiple Myeloma Research Foundation), Santiago Thibaud(Icahn School of Medicine at Mount Sinai), Ajai Chari(University of California, San Francisco)
Cited by 103
Related Papers
Nivolumab plus Ipilimumab in Advanced Melanoma
|New England Journal of Medicine|2013|4.2k
An inflammatory cytokine signature predicts COVID-19 severity and survival
|Nature Medicine|2020|2.7k
Efficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic Leukemia
|Science Translational Medicine|2014|2.5k
Immunologic Correlates of the Abscopal Effect in a Patient with Melanoma
|New England Journal of Medicine|2012|2.1k
Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma
|New England Journal of Medicine|2019|1.7k